Cost Of Failure Following Reimplantation After a 2-Stage Exchange Strategy For Hip Or Knee Prosthetic Joint Infection

Overview

This study concerns patients having had an infection on their prosthesis (hip, knee,..) and for whom a 2-step exchange of prosthesis has been done. A 2-step exchange consists in explantation of the prosthesis and implementation of a spacer at the first stage, and reimplantation of a new prosthesis in a second stage. Patients with late prosthetic joint infection are at risk for superinfection at the time of reimplantation. The aim of this study is to determine the global cost of management of prosthetic joint infection.

Full Title of Study: “Cost of Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 1, 2018

Interventions

  • Other: Global cost of management of PJI
    • estimation of the global cost to manage PJI with 2-step exchange over 3 years

Arms, Groups and Cohorts

  • Global cost of management of PJI

Clinical Trial Outcome Measures

Primary Measures

  • Global cost of management of PJI
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
    • The following data are collected : duration of hospitalization at the Croix Rousse hospital (surgery unit, department of infectiology, other…) and in post-acute care structures, bacteriology, surgeries, medical treatments… and all acts realized throughout the management of the PJI.

Participating in This Clinical Trial

Inclusion Criteria

  • patients with prosthetic joint infection having had a 2-step exchange and managed at the CRIOAc from at least the reimplantation (between 2013 and 2015) Exclusion Criteria:

-

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Collaborator
    • Heraeus Medical GmbH
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tristan Ferry, Md,PhD, Principal Investigator, Hospices Civils de Lyon – Hôpital de la Croix-Rousse

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.